Medicine guide

Bimervax

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Bimervax is indicated as a booster for active immunisation to prevent COVID-19 in individuals 12 years of age and older who have previously received a mRNA COVID-19 vaccine (see sections 4.2 and 5.1). The use of this vaccine should be in accordance with official recommendations. Bimervax XBB.1.16 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations. Bimervax LP.8.1 is indicated for active immunisation to prevent COVID-19 caused by SARS CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.

From the official label · 2026-09-30 · European Medicines Agency

Made by	Hipra Human Health S.L.
Active substance	COVID-19 Vaccine (recombinant, adjuvanted)
Used in	Antibiotics, antivirals and antifungals taken into the body
Classification	J07BN · Antibiotics, antivirals and antifungals taken into the body
Additional monitoring ▼	Yes — under additional monitoring (black triangle). Report suspected side effects.
Authorised on	2023-03-30
Last updated by the regulator	2026-08-04
EMA product number	EMEA/H/C/006058

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

These contain the same substance. That does not mean one can replace another — ask a pharmacist.